Rapid response of severe refractory metastatic Crohn's disease to infliximab

J Gastroenterol Hepatol. 2001 Aug;16(8):940-2. doi: 10.1046/j.1440-1746.2001.02439.x.

Abstract

A case is described of a middle-aged female who developed an aggressive form of biopsy-proven metastatic Crohn's disease involving the inguinal, perineal and submammary areas. Her condition had been unresponsive to topical and systemic corticosteroids, antibiotics, immunosuppressives, and repeated surgical debridement. Administration of infliximab resulted in a rapid clinical response with subjective improvements in pain and general well-being, and an objective decline in exudate, erythema and size of the lesions. Infliximab may be a suitable therapeutic option in patients with metastatic Crohn's disease.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Crohn Disease / complications
  • Crohn Disease / drug therapy*
  • Crohn Disease / pathology
  • Female
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Infliximab
  • Middle Aged
  • Skin Diseases / etiology
  • Skin Diseases / pathology

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Infliximab